Skip to main content
BSCS logo
BSCS
(NASDAQ)
Invesco BulletShares 2028 Corporate Bond ETF
$20.31-- (--)
Loading... - Market loading

BSCS ETF: Invesco BulletShares 2028 Corporate Bond ETF - Price, Holdings & Analysis

Invesco BulletShares 2028 Corporate Bond ETF Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$20.39 - $20.41
52-Week High$20.69
52-Week Low$20.30
Open$20.41
Volume547.07K
Average Volume (3M)510.79K
Assets (AUM)3.50B
Expense Ratio0.10%
Total Holdings475
Inception DateAug 8, 2018
1 Day Change0.15%
1 Month Change0.25%
6 Month Change-1.14%
YTD Change-1.04%
1 Year Change-0.27%
52-Week Change-0.12%
5 Year Change-11.71%
50-Day MA$20.41
200-Day MA$20.53
RSI49.43
Stochastic %K50.00
Stochastic %D51.85
Annual Dividend$1.21
Dividend Yield5.93%
Last Dividend Ex-DateJun 27, 2026
Dividend Growth YoY30.63%
Years Dividend Growth4

Frequently Asked Questions About Invesco BulletShares 2028 Corporate Bond ETF

What is the current price of BSCS?

The latest BSCS price is $20.39. The 52-week range is $20.30–$20.69. BSCS has returned -0.1% over the past 52 weeks.

What is the expense ratio for BSCS?

BSCS's annual expense ratio is 0.10%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Fixed Incomes in the ETF Screener.

Does BSCS pay dividends?

Yes, BSCS pays a 5.93% dividend yield. The last ex-dividend date was 2026-06-27. View full dividend history in the Dividends section.

What are the top holdings of BSCS?

BSCS's largest holdings are CVS Health Corp 4.3% (1.2%), Amgen Inc. 5.15% (0.9%), The Cigna Group 4.375% (0.9%) (combined weight: 3.0%). The fund holds 475 total positions. View the complete portfolio breakdown in the Holdings section.

How does BSCS compare to similar ETFs?

Compare BSCS (0.10% expense ratio, $3.50B AUM) against similar Fixed Incomes using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.